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Background: Urinary tract infection (UTI) is common in children, and may cause serious illness and recurrent
symptoms. However, obtaining a urine sample from young children in primary care is challenging and not feasible
for large numbers. Evidence regarding the predictive value of symptoms, signs and urinalysis for UTI in young
children is urgently needed to help primary care clinicians better identify children who should be investigated for
UTI. This paper describes the protocol for the Diagnosis of Urinary Tract infection in Young children (DUTY) study.
The overall study aim is to derive and validate a cost-effective clinical algorithm for the diagnosis of UTI in children
presenting to primary care acutely unwell.
Methods/design: DUTY is a multicentre, diagnostic and prospective observational study aiming to recruit at least
7,000 children aged before their fifth birthday, being assessed in primary care for any acute, non-traumatic, illness
of≤ 28 days duration. Urine samples will be obtained from eligible consented children, and data collected on
medical history and presenting symptoms and signs. Urine samples will be dipstick tested in general practice and
sent for microbiological analysis. All children with culture positive urines and a random sample of children with
urine culture results in other, non-positive categories will be followed up to record symptom duration and
healthcare resource use. A diagnostic algorithm will be constructed and validated and an economic
evaluation conducted.
The primary outcome will be a validated diagnostic algorithm using a reference standard of a pure/predominant
growth of at least >103, but usually >105 CFU/mL of one, but no more than two uropathogens.
We will use logistic regression to identify the clinical predictors (i.e. demographic, medical history, presenting signs
and symptoms and urine dipstick analysis results) most strongly associated with a positive urine culture result. We
will then use economic evaluation to compare the cost effectiveness of the candidate prediction rules.
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Discussion: This study will provide novel, clinically important information on the diagnostic features of childhood
UTI and the cost effectiveness of a validated prediction rule, to help primary care clinicians improve the efficiency
of their diagnostic strategy for UTI in young children.
Keywords: Urinary Tract Infection, Children, Primary care, Point-of-care-test, Dipstick test, Near-patient testing,
Diagnosis, Economic modelsBackground
Acute illness in young children is one of the commonest
reasons for seeking health care worldwide. Reported
rates of urinary tract infection (UTI) in children consult-
ing for any acute condition vary widely (from 2% to 20%
depending on setting and inclusion criteria) and most of
this research has been hospital based [1,2]. Only one
study has systematically sampled urine from sequentially
presenting acutely unwell children in primary care, and
found UTI prevalence of 4% [3]. However, that study
was not adequately powered to estimate the predictive
value of symptoms and signs with adequate precision.
UTI may be missed in as many as 50% of young chil-
dren presenting to primary care [4,5]. The clinical diag-
nosis of UTI in young children is difficult because: (1)
pre-verbal (predominantly under 3 years) children can-
not articulate symptoms and present with the same non-
specific symptoms (e.g. fever, irritability, vomiting and
poor feeding) when suffering from a wide range of ill-
nesses [6]; (2) identifying dysuria and changes in urin-
ation frequency in children wearing nappies (diapers) is
difficult; (3) obtaining urine samples is often challenging
and time consuming for parents[1] and costly to the
health service [7,8]; and (4) the National Institute for
Health and Clinical Excellence (NICE) does not recom-
mend routine urine dipstick testing in children under
3 years because of a lack of research evidence as to its
diagnostic value [9]. UTI diagnosis is therefore often
delayed [6], missed [4] or symptoms attributed to other
causes (such as otitis media) [10].
UTIs in young children may cause acute morbidity
and recurrent symptoms that may indicate functional
and anatomical abnormalities. In some young children,
UTI may lead to renal scarring [11], leading to poor
renal growth, recurrent pyelonephritis, impaired glom-
erular function, early hypertension, end stage renal dis-
ease [12] and pre-eclampsia [13-15]. Some experts,
therefore, recommend aggressive, early antibiotic treat-
ment for symptoms suggestive of UTI in young children
to prevent renal scarring [16].
Dramatic reductions during the second half of the
1990s and early 2000s in antibiotic prescribing for chil-
dren with upper respiratory infections [17] may have
reduced serendipitous treatment of undiagnosed UTI
and the consequent prevention of renal scarring.However, antibiotic prescribing in the UK may now be
on the increase [18]. NICE promotes early recognition
and treatment to prevent short-term suffering and pos-
sibly serious long-term complications [9]. However,
increased urine sampling will increase costs, consult-
ation length and frequency of consultations in primary
care. Clinicians will therefore only increase their sam-
pling rates if evidence shows this really does improve the
identification of UTI among the many acutely unwell
children consulting primary care.
To date there is a lack of evidence as to the clinical
predictors of UTI in young children. A meta-analysis [1]
including 8,837 mostly pre-verbal children from 12 stud-
ies, showed that fever, non black race, a history of a pre-
vious UTI, temperature higher than 40°C, and
suprapubic tenderness were the findings most useful for
identifying those with a UTI. Uncircumcised boys were
also more likely to have a UTI. While individual symp-
toms and signs were helpful in the diagnosis of a UTI,
they were not sufficiently accurate to definitely rule it in,
however a combination of findings could identify infants
with a low probability of UTI [1]. The applicability of
this review to UK general practice is limited because: (1)
included studies were set in the US private and emer-
gency care system where consultation and investigation
threshold differs from UK primary care and other health
care systems that are free at the point of delivery; (2)
children had to either already have symptoms of UTI or
fever ≥38°C, so many subtle symptoms and signs may
not have been considered; (3) urine sampling was by
catheter or suprapubic aspiration (which is not con-
ducted in most primary care settings world-wide and
from which any bacterial growth is regarded as signifi-
cant); (4) diagnostic criteria used were different (≥104
colony forming units per millilitre (CFU/mL)) to UK
practice (≥105 CFU/mL); (5) the relationship between
ethnicity and UTI could be confounded; and (6) none of
the studies included in the meta-analysis checked the ex-
ternal validity [19] of the findings, meaning that esti-
mates of association could be inflated [20].
A more recent review of primary care based paediatric
studies using urine culture as the reference standard
found that no individual symptom or sign, or any com-
bination of symptoms or signs, was sufficient to rule in a
diagnosis of UTI, although some (e.g. increased capillary
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appear to warrant urine testing and empirical treatment
while awaiting culture confirmation [2]. Furthermore, a
number of symptoms and signs did not appear to have
diagnostic value, including some of those included in the
NICE guidelines (e.g. poor feeding and vomiting). Some
symptoms, signs and proposed clinical prediction rules
were associated with a sufficiently low UTI probability
to rule out UTI, thereby removing the need to obtain a
urine sample [1-3].
We found only one clinical algorithm derived from
primary research for the diagnosis of UTI in young chil-
dren. The research included febrile girls aged under two
years in one US Emergency Department [21] and was
validated in a case–control study in a different Emer-
gency Department [22]. They found that more than
three findings of: aged less than 12 months; white race;
temperature of ≥39°C; absence of any other likely
source of fever; or fever for 2 or more days gave an area
under the curve of 0.72, a sensitivity of 88% (95% CI:
79% to 94%) with a false-positive rate of 70% (95% CI:
61% to 79%).
An additional issue for the diagnosis of UTI in chil-
dren is uncertainty as to the best criteria for microbio-
logical diagnosis of UTI in this age group. Historically
this has been based on a colony count of bacteria in the
urine with a cut-off of ≥105 colony forming units (cfu)/
mL of a uropathogen indicating infection. However this
was derived from studies in adult women [23] and its
applicability to children has been questioned by NICE
[9] and others. Current guidance for microbiological
diagnosis of UTI in children is at variance. The UK Na-
tional Standard Method suggests that colony counts of
≥103 cfu/mL of a single species may be diagnostic of
UTI in voided urine and that a pure growth of between
104–105 cfu/mL is indicative of UTI in a carefully taken
specimen [24]. For midstream specimens, the European
Association of Urology, suggests a cut-off of ≥104 cfu/
mL if associated with symptoms, but ≥105 cfu/mL if
symptoms are absent; lower cut-offs are suggested for
PSA and bladder catheterisation samples [25]. However
guidance from the American Academy of Pediatrics sug-
gests that both urinalysis suggesting infection (pyuria
and/or bacteriuria) plus the presence of ≥ 5x104cfu/mL
of a uropathogen are required for a diagnosis of UTI, al-
though these guidelines are for urine specimens
obtained through catheterization or an SPA, which
would not be routine in the UK [26].
Additional value of dipstick testing in young children
A 2006 Health Technology Assessment (HTA) review
found there was inadequate evidence on the diagnostic
performance of dipstick tests for protein or blood for
children aged under 5 years old. The combination of apositive test for both nitrite and leucocyte esterase (LE)
was most accurate for ruling in UTI (pooled LR+ 28.2
(95% CI: 17.3 to 46.0)), and a negative test for both ni-
trite and LE was most accurate for ruling out UTI
(pooled LR- 0.20 (95% CI: 0.16 to 0.26)) [27]. The NICE
UTI guideline development group concluded that there
was insufficient evidence to recommend the use of dip-
stick urine tests for children under 3 years [9].
Economic impact of UTI
UTI is the fourth most common reason overall for pre-
scribing antibiotics in UK general practice, accounting
for approximately 8% of all antibacterial prescriptions .
However, UTI is currently infrequently diagnosed in
children [28]. Whilst the unit costs of laboratory testing
and antibiotic prescribing are relatively low [27], the eco-
nomic implications of new clinical algorithms for urine
sampling and testing may be substantial in young chil-
dren because of: (1) the large numbers of children who
present with non-specific symptoms who might be can-
didates for urine sampling and testing; (2) the cost, to
healthcare services and to patients, of subsequent diag-
nostic tests (e.g. ultrasound, Micturating Cystourethro-
gram (MCUG) and Dimercaptosuccinic Acid (DMSA)
scans) used to further evaluate children with recurrent/
atypical UTI [9]; (3) the substantial societal costs and
utility detriments of a missed diagnosis that leads to rare
but serious complications of UTI; and (4) the wider,
long-term population impact of diagnostic algorithms on
antibiotic prescribing and resistance [29].
The few economic evaluations of methods for diagnos-
ing UTI in young children [27,30] have primarily evalu-
ated ‘which tests to use?’ rather than ‘who to test?’ The
2006 HTA review [27] evaluated 79 permutations of dip-
stick, cultures, ultrasound, and MCUG, and identified
four testing strategies most likely to be cost-effective, al-
though the optimal strategy differed by gender and age
group. Current NICE guidance on testing strategies for
UTI in children under 3 years is not based on evidence
of cost-effectiveness [9].
Research objectives
In summary, rigorous evidence regarding the predictive
value of symptoms, signs and urinalysis for UTI in
young children is urgently needed to help primary care
clinicians better identify UTI. Furthermore, since obtain-
ing urine samples is especially challenging in children
aged before their fifth birthday, the resulting algorithm
will be constructed to answer two separate questions:
first, which children warrant urine sampling? And sec-
ond, can point of care dipstick urinalysis help clinicians
determine which samples should be sent for laboratory
culture? The algorithm will then be the subject of a val-
idation study. Furthermore, since changes in the
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implications for parents and for healthcare services, ana-
lyses will model the economic impact (from the NHS
and societal perspectives) of GP judgement versus diag-
nostic algorithm guided diagnosis and management with
respect to the cost per correctly identified UTI, cost per
symptomatic day avoided and the cost per quality
adjusted life year.
The Diagnosis of Urinary Tract Infection in Young
Children (DUTY) study protocol has the following re-
search objectives:
1. To develop candidate clinical prediction rules that
accurately identify children presenting in primary
care with an acute illness in whom a urine sample
should be obtained, based on socio-demographic
factors, medical history, symptoms and signs.
2. To assess whether dipstick urinalysis for nitrite,
leukocyte esterase, protein, blood and glucose gives
additional diagnostic information to objective (1) in
the identification of urine samples that should be
sent for laboratory analysis.
3. To model cost-effectiveness from NHS and societal
perspectives of the candidate clinical prediction rules.
4. To compare contamination rates for different urine
sampling methods.
Methods/Design
Ethical and governance approval
Multi-centre approval was granted by the South West
Southmead Research Ethics Committee (previously
Southmead Research Ethics Committee, then South
West 4 REC), Ref #09/H0102/64. Research and Develop-
ment (R&D) approval has been granted for all sites tak-
ing part in the study.
Design
DUTY is a 3-year, multicentre, diagnostic accuracy study
to derive and validate a cost effective algorithm for the
diagnosis of UTI in children under 5 presenting to pri-
mary care with an acute illness.
Children are eligible if they are aged before their fifth
birthday and present to primary care with a new acute
illness episode of less than or equal to 28 days duration.
A Case Report Form (CRF) will be completed for all eli-
gible, consented children and a urine sample obtained.
The prevalence of UTI will be determined on laboratory
culture. An algorithm will be derived and validated in
separate samples of children.
Setting
This UK study will be implemented from four research
centres at the Universities of Bristol, Cardiff, Southampton
and King’s College London. Each centre will recruitchildren from primary care, defined as any NHS facility
providing first-point-of-contact face-to-face advice for
parents of unwell children (GP practices, Walk-in-Centres
(WIC), and Children’s Emergency Departments (CED)).
Study procedures
Primary care sites/GP practice recruitment
Primary care sites will be recruited by each study centre
covering both urban and rural areas across England and
Wales. Two models of recruitment will be offered: (1) Op-
tion 1, in which the majority of the recruitment proce-
dures will be undertaken by a dedicated Research Nurse
(RN) or Clinical Studies Officer (CSO) external to the site;
and (2) Option 2, in which recruitment will be undertaken
entirely ‘in house’ by the primary care site’s clinical team.
From now on, members of staff taking informed consent
for the DUTY study will be referred to as “recruiting clini-
cians”. Dedicated RNs/CSOs providing external support
for sites will be referred to as “DUTY recruiters”, while
members of practice staff involved in option 2 recruitment
will be referred to as “site-based recruiters”.
Recruiting staff
The study grant will provide full-time equivalent DUTY
recruiter posts across all four study centres, which will
be supplemented by additional DUTY recruiter posts
provided by local Primary Care Research Networks
(PCRNs) and Comprehensive Local Research Networks
(CLRNs) (in England) and by the National Institute for
Social Care and Health Research – Coordinating Re-
search Centre (NISCHR-CRC) (in Wales). These DUTY
recruiters will be available to provide Option 1 support
to primary care sites, and to support autonomously
recruiting Option 2 sites through the provision of expert
training, mentoring and problem-solving.
NHS microbiology laboratory recruitment
The participation of any primary care site in recruitment
to the study will depend on the support and participa-
tion of the local NHS microbiology laboratory to which
the site routinely sends urine samples. In each area of
recruitment, the local NHS laboratory will be
approached and service level agreements put in place
prior to involvement in the study.
Participant recruitment
The recruitment process is summarised in Figure 1.
Registration and consent
Parents and children may be invited to take part in the
study in a number of ways:
1. Where possible, primary care sites will mention the
study to parents of children under 5 when they
Parents of children under 5 years of age who have approached 
the surgery and requested an appointment are identified by 
reception staff or nurse and given information about the study 
and asked to indicate if they would like to see the RN/CSO 
before they see the clinician
12-21  day follow-up by telephone 
(for those >105CFU ml and a sample <105 CFU ml using proportional 
selection rules in Table 2)
A second voucher is posted to the parent from the study centre as a 
‘Thank You’ token for taking part in the interview.
Parent & child see Doctor/Nurse who
• Answers questions about the study
• Assesses eligibility
• Records diagnostic & examination 
information
Parent & child see Doctor/Nurse who
• Records diagnostic & examination 
information
Urine sample provided to RN/CSO
(either during visit or done at home and returned to the surgery). 
Parent receives voucher from RN/CSO as a ‘Thank You’ token.
Urine sample tested with dipstick by RN/CSO, result passed to clinician and 
recorded on CRF/website.
Management due to local clinical practice
Indicates that the parents can choose  to  participate either before or after the child 
sees the doctor/nurse.
3 month medical notes review
(for those>105CFU ml and a sample>105CFU ml using proportional     
selection rules in Table 2) 
Parent & child  see RN/CSO who  
• Answers questions about the study
• Assesses eligibility
• Takes consent
• Collects basic information
• Explains to parents how to get urine 
sample
Parent & child see RN/CSO who
• Takes consent
• Collects basic information
• Explains to parents how to get a  urine 
sample
Figure 1 DUTY participant flow diagram.
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the surgery 15 minutes early to receive further
information.
2. Where the study was not raised at the time of
making the appointment, parents of children already
booked in may be phoned and told about the study
and invited to attend a little earlier.
3. If they cannot be contacted by telephone, they will
be approached on arrival at the site, given
information sheets and asked if they would be
happy to see a recruiting clinician to discuss
participation.
Once the parent has indicated they are happy to dis-
cuss the study, the recruiting clinician will explain study
participation answer any questions that the parent may
have, ensure that they fully understand the implications
of participation, and check the child’s eligibility. If the
child is eligible and the parent agrees to participate, writ-
ten informed consent will be obtained from the parent.
If the parent wishes to see the GP before consenting, the
recruiting clinician will arrange for this to happen, with
the parent and child returning to the recruiting clinician
afterwards to complete recruitment. Where possible the
recruiting clinician will recruit the participant while they
are waiting to see the GP, in order that the parent and
child are not delayed. However, if more practical or con-
venient, the recruiting clinician may offer, with the par-
ent’s permission, to visit the family later the same day at
their home to complete recruitment. If the parent is not
interested in hearing more about the study, no further
approach will be made.Non-registration
A screening log of all children aged before their fifth
birthday, who are attending for care and whose parents
are approached by the recruiting clinician to invite par-
ticipation in the study, will be compiled. Details will be
recorded as to their eligibility, whether consent was
given or declined, and reason for declining to
participate.Participant eligibility
Table 1 details the inclusion and exclusion criteria for
the study. Since ruling out UTI may be as important as
ruling it in, the study inclusion criteria were designed to
be as broad as possible. Therefore, children consulting
with other ‘obvious’ causes for their symptoms such as
otitis media or bronchiolitis, as well as those with a his-
tory of previous UTI and known abnormalities of the
urinary tract, learning difficulties, or re-consulting for an
existing illness are all included as long as none of the ex-
clusion criteria apply.The study will include parents who speak other (non-
English) languages. Parent information sheets and con-
sent forms will be translated into other languages as
required by participating GP practices (e.g. Welsh, Polish
and Brazilian Portuguese). For languages less commonly
spoken in the UK, particularly for those in which oral
translation is more useful than written translation (e.g.
Somali), translational services will be accessed, where
possible, via interpreters employed by recruiting primary
care sites to support patient-clinician communications.
Where these services are not available, translational ser-
vices will be provided via Language Line.
Collecting urine samples and dipstick testing
The recruiting clinician will attempt to obtain a urine
sample from the children of consenting parents during
the recruitment visit. If this is not possible, the recruit-
ing clinician will ask the parent to collect the sample at
home, give them the appropriate equipment and explain
how to collect it. To minimise contamination, urine
samples will be obtained using the ‘clean catch’ where
this is possible. Where this is not possible, the ‘nappy
pad’ method (which involves cleaning the child’s peri-
neum and inserting a sterile pad into the nappy to soak
up urine, for a maximum period of 1 hour) will be used,
as described by Liaw et al. [31] and as recommended by
the recent NICE guidelines [9]. Urine sampling can be
underway whilst the recruiting clinician completes the
study CRF.
The recruiting clinician will retrieve the urine sample,
test it with a urine dipstick (Siemans/Bayer multistix
8SG) provided by the study and record the urine sam-
pling method and dipstick result on the CRF. The urine
sample will then be split, if sufficient quantity is avail-
able, with the priority fraction being sent to the local
NHS laboratory for routine diagnostic processing, and
the second ‘research’ fraction being sent to the SACU
(Specialist Antimicrobial Chemotherapy Unit, Public
Health Wales Microbiology Cardiff, University Hospital
of Wales) reference laboratory: for more in-depth ana-
lysis. As only small volumes of urine (minimum 1 mL)
are required for each laboratory, it is expected that for
most urine samples, it will be possible to split the urine
into the two fractions.
If a sample is not obtained during this visit the parent
will be asked if they could obtain one at home, refriger-
ate it and return it to the primary care site within 24
hours. Where possible, the DUTY recruiter will offer to
collect the urine sample from the patient’s home.
In a sub-sample of children recruited from a handful
of sites linked to the Bristol study centre, we will use
time-motion techniques to measure the additional time
(parent and healthcare professional) taken to collect the
urine sample and to perform dipstick testing during the
Table 1 DUTY eligibility criteria
Children will be included if: Children will be excluded if:
Aged before their fifth birthday. Aged 5 years and above.
Presenting at a participating NHS primary care site. Parents are unable or unwilling to assist with study.
Presenting with an acute (≤28 days) illness as the main reason for the
parent to have requested an appointment.
Illness longer than 28 days duration.
Presenting with trauma as a predominant concern.
Presenting with at least one ’constitutional’ symptom or sign identified by
NICE [9] as a potential marker for UTI – that is, fever, vomiting, lethargy/
malaise, irritability, poor feeding and failure to thrive and/or at least one
urinary symptom identified by NICE [9] as a potential marker of UTI – that
is, abdominal pain, jaundice (children <3 months only), haematuria,
offensive urine, cloudy urine, loin tenderness, frequency, apparent pain on
passing urine and changes to continence.
No urinary or constitutional symptoms as defined by NICE [9] and listed
in the left hand column.
Known neurogenic (e.g. spina bifida) or surgically reconstructed bladder
or urinary permanent or intermittent catheterisation (for whom different
bacterial concentration cut points are used).
Taking any antibiotics in the last 7 days.
Taking immunosuppressant medication (e.g. anti-rejection drugs, oral or
intramuscular steroids or chemotherapy).
Already recruited into the DUTY study.
Involved in current research or have recently (within 28 days) been
involved in any research prior to recruitment.
There will be no recruitment to the study after the last NHS laboratory
transport of the day has departed from that primary care site on Fridays.
For recruitment at A&E settings only: children will not be eligible if their
presentation at A&E is a direct result of GP referral.
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form the economic analysis.
Maximising urine samples
Obtaining the urine samples will be challenging, and a
suboptimal return rate will diminish power and increase
risk of bias. Therefore: (1) we will monitor the location
of urine specimens using a web-based database. Clinical
data for recruited children will be logged onto the secure
study website. Dipstick urinalysis data may be added
after the clinical data and will provide a record of the
urine having been obtained. This will allow the research
team to identify children for whom urine samples have
not been provided, and to check with the relevant re-
cruiter as to whether this should be followed up. Both
the Research and NHS laboratories will also record the
arrival of, and results from, the specimens on the web-
site; and (2) each centre will provide dedicated DUTY
recruiter resource to assist Option 1 practices with
obtaining urines.
Laboratory processing of urine samples
The NHS ‘clinical’ fraction will be labelled with the
child’s unique DUTY study identification (ID) number
on DUTY specific labels as provided in patient packs.
Similar DUTY labels will be adhered to the DUTY study
specific microbiology form and the sample sent to the
local laboratories using the site’s normal method of
transport. Any samples not collected within 4 hours will
be refrigerated at the site and processed within 36 hours.
Clinicians will receive and act on reports from their local
laboratory as in the course of usual clinical care.The remaining portion of urine will be decanted into a
sterile monovette container containing boric acid. This
will be labelled with the child’s study ID number and
sent by 1st Class Royal Mail using Post Office approved
SafeboxesTM to the central research laboratory.
Minimising effects of sample contamination and
assessment of asymptomatic bacteriuria
Contamination of urine (a cultured organism from a
source other than the urinary tract) can lead to false
positives: a potential false positive rate of 7.2% has been
identified in one study by comparing pairs of urines
from 203 children [32]. All nine (5.4%) children in this
study with a mixed culture ≥105 CFU/mL of uropatho-
gens (a heavy mixed growth) in their first sample had a
UTI excluded in the second [32]. In addition, bacteria at
≥106 CFU/mL (have also been found in the urine of ap-
proximately 1.5% of young, asymptomatic, children
when screened using the ‘gold standard method’, supra-
pubic aspiration [33], and most did not experience long
term sequelae [34]. Therefore, distinguishing UTI from
asymptomatic bacteriuria and bacterial contamination is
difficult, and could lead to spurious associations between
symptoms (e.g. diarrhoea) and apparent ‘UTI’ that is in
reality contamination or potential harmLess asymptom-
atic carriage.
Clinicians use the presence of UTI symptoms to help
interpret culture positive results but this leads to incorp-
oration bias. In DUTY, we could restrict recruitment to
those children with currently recognised symptoms of
UTI, but since the purpose of DUTY is to determine the
strength of association between currently recognised as
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it is important that eligibility criteria are as ‘open’ as
possible (and that a prospective cohort, as opposed to
retrospective case–control, design is used), but without
including children in whom a positive culture is unlikely
to be clinically relevant (e.g. a well child with conjunctiv-
itis). Therefore, DUTY will recruit children with consti-
tutional and/or urinary symptoms and make the
assumption that the presence of no more than two
pathological bacteria of at least >103, but usually
>105 CFU/mL on culture of their urine is clinically sig-
nificant. This could result in more urine samples being
tested and more children receiving antibiotics than is
strictly necessary, but carries the benefit that more UTIs
would be identified and treated promptly.
Data collection
Unique study identification numbers will be sequen-
tially generated and used on pre-printed consent
forms, paper CRFs, urine sample labels and test re-
quest forms (for local NHS and central research
laboratories).
A CRF will be completed for all consented patients.
This will include a short medical history including re-
cent antibiotic use and other potential risk factors for
UTIs and resistance, and clinical examination findings.
An outline of the domains covered in the CRF can be
found below in the next section.
Case report form
The CRF will contain as many of the known and poten-
tial features associated with UTI as are feasible without
overly compromising the speed and simplicity of
completion.
Five sections will facilitate data entry by different
personnel (recruiter taking consent or responsible clin-
ician) so as to minimise the burden to healthcare profes-
sionals undertaking same day primary care:
1. Eligibility screening and consent (to be completed by
recruiting clinician within the recruitment interview
with the parent).
2. Registration (to be completed by recruiting clinician
as above): Socio-demographic data (to include: date
of consultation, name, address, contact telephone
number/s, ethnicity [21], date of birth and gender
[9]). We will also ask about parent’s highest
educational attainment level and their financial well-
being in order to assign a measure of socio-economic
deprivation.
3. Presenting Symptoms and Medical History (to be
completed by recruiting clinician as above): child’s
presenting symptoms will be recorded, along with
known previous medical history (e.g. previous UTI,circumcision [5,35], child or family history of vesico-
ureteric reflux [36], other abnormalities of the
urinary tract, learning difficulties, details of prior
surgery, other co-morbidities, recent and previous
long-term use of medicines, including antibiotics).
4. Clinical Examination and Management (to be
completed by child’s responsible clinician within a
standard consultation): in addition to the
‘constitutional’ and ‘urinary’ study eligibility
symptoms defined by NICE [9], we will collect
information regarding the clinician’s global
assessment of illness severity [37], respiratory and
gastro-intestinal symptoms and signs, and the
symptoms and signs proposed by NICE to
distinguish ‘typical’ from ‘atypical’ UTI, such as poor
urinary flow and abdominal mass.
Clinicians will be asked to record the child’s
management, including antibiotic use and immediate
referral to secondary care. To assess the diagnostic
value of the urine dipstick test, we will ask clinicians
to record their working diagnosis before having seen
the dipstick results, and to record whether their
working diagnosis has changed after they have seen
them. Finally, for the economic analysis, we will ask
clinicians to state what their management would be
if the patient were not enrolled in the DUTY study
(e.g. no urine test/not treated for UTI or urine test/
treat for UTI). This will provide information on the
‘clinician judgement’ diagnostic strategy that will be a
comparator in the economic evaluation.
5. Urine collection and processing (to be completed by
recruiting clinician): Urine sampling method (clean
catch or nappy pad) and urinalysis results with date,
time of testing, with a prompt to inform the
responsible clinician of dipstick result and
confirmation that the sample has been sent to the
local NHS and central research laboratories.
In addition to the CRF, the study web-based data col-
lection platform will include additional sections to cover
data entry for the following: (1) NHS microbiology la-
boratory microscopy and culture; (2) SACU research la-
boratory microscopy and culture; (3) patient follow-up
at Day 14 following recruitment, and (4) patient notes
review at 3 months from recruitment. Further detail of
the content of these domains is provided below.
Processing of urine samples by NHS laboratories
NHS laboratories will be informed of the study and the
agreement of the lead consultant microbiologist, labora-
tory manager and the NHS hospital Research and Devel-
opment approval obtained before patient recruitment
begins. The laboratories will be asked to complete the
following tasks for DUTY study samples:
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secure DUTY web-based database.
2. Process the urine and report the result back to the
requestor using their own Standard Operating
Procedures (SOPs) and Laboratory Information
Management Systems (LIMS).
3. Enter the results of urine culture onto the DUTY
study web-based database. Since laboratories vary in
their SOPs, not all of the following will be available
however, microscopy for white and red cells;
quantification and purity of bacterial growth; and
speciation will be requested. Laboratories will be
asked to transcribe this information onto the DUTY
web-based database in order to activate laboratory
payment.
4. Store any isolates from urines with >105 CFU/mL in
pure/predominant ureopathogen growth for referral
onto the central research laboratory at the end of the
study. These should be stored, ideally on cryogenic
beads, at temperatures of -70 C, or on slopes at
-20 C if -70 C storage facilities are not available.
Processing of urine samples by the research laboratory
The central research laboratory has experience in sup-
porting other primary care UTI studies and performed a
similar role to that described below in the previous EUR-
ICA study (Epidemiology of urinary tract infection in
children with acute illness in primary care) [3].
1. Urines will be sent overnight by Royal Mail
SafeBoxesTM by the participating sites. Boric acid will
be used to stabilise bacterial counts.
2. On receipt at the central research laboratory, the
urine sample will be spiral-plated on blood agar and
UTI Chromogenic agar will be used to quantify
bacteria >2x101 CFU/mL and <1010 CFU/mL.
3. The bacteria will be identified to species level and
stored on cryogenic beads at −80°C. The urine will
be stored frozen.
4. Results will be recorded on a designated laboratory
worksheet and entered into the DUTY web-based
database.
Where the urine culture result produced by the central
research laboratory is positive and the local NHSTable 2 Proportional selection rules for DUTY follow-up
Category Definition Location
> 105 CFU/ml Pure or 1 predominant species BOTH NHS lab
>103 and < 105 CFU/ml Pure or 1 predominant species Central researc
>105 CFU/ml 2 or more species BOTH NHS lab
< 103 CFU/ml and ‘No
Growth’
BOTH NHS lablaboratory result is negative or not processed, and if this
discrepancy is considered by the lead SACU microbiolo-
gist to be clinically significant, we will inform the child’s
responsible clinician. This will enable the child’s respon-
sible clinician to consider the future management of the
child in the light of the additional information arising
from the study.Patient follow-Up
Telephone follow-up at Day 14
Each centre will telephone parents of all children
selected for follow-up according to the proportional se-
lection rules in Table 2, to record symptom duration and
healthcare resource use (e.g. repeat primary care con-
tacts other community care, secondary care contacts,
prescribed and over-the-counter medications) during the
14 day period after recruitment. Parents will also be
asked to detail expenses and time off work due to
their child’s illness and rate the child’s quality of life
(including symptoms, sleeping, feeding, behaviour
and wellbeing) using a previously validated measure
(TAPQoL) [38].3 Months note review
Each research centre will conduct a primary care notes
review for all children who were selected for follow-up.
Primary care contacts, medications and secondary care
utilisation during the 3 months after study recruitment
will be recorded during the review.Withdrawal & loss to follow-Up
In the majority of cases the only active participation of
participants is at the initial consultation, and withdrawal
from the study in most cases is unlikely. Attrition in
those selected for 14 day follow-up due to the challenges
of making contact with busy parents will be minimised
by making several attempts to contact parents/guardians
by telephone and, if this is unsuccessful, a postal version
of the resource use questionnaire will be posted to parti-
cipants with a stamped addressed envelope for return.
Parents will be offered a £5 voucher, by post, on comple-
tion of follow-up either by telephone or post.Proportion to be sampled at Day 14
and Central research lab 100% (All)
h lab 20% in total (combination of both categories)
and Central research lab
and Central research lab 10%
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The DUTY data collection process is complex and
involves input from a number of different personnel
at different sites: (1) CRF data by a combination of
study DUTY recruiters, practice nurses, GPs and
dedicated staff at recruiting primary care sites; (2)
clinical and research urine culture results by labora-
tory technicians and managers; and (3) follow-up data
at Day 14 and 3 months by study centre administra-
tors and research nurses. To optimise the quality of
the data entry and to enable effective data collection
from multiple sites across England and Wales, we
decided to use a secure, web-based electronic data
collection platform.
We will use a secure web 2.0 clinical study manage-
ment system (The electronic Primary Care Research
Network (ePCRN)). Hosted by South London and
Maudsley (SLAM) NHS Foundation Trust, the ePCRN
implementation is of a separate domain and a Citrix
farm serving published applications, with a Structured
Query Language (SQL) server providing clinical based
study application databases. The system avoids poten-
tial data loss, duplication and security issues with lap-
tops and portable media and has been approved by
ethics and by the SLAM Caldicott and Executive
Committees.
Web-forms for data collection will be created in ASP.
net (a dynamic web application framework) on top of a
dedicated SQL data management server, with data vari-
ables forced to comply with entry and validation rules
defined in the data element definitions. The SQL data
management server will incorporate auditing, backup
and recovery facilities. The study workflow and algo-
rithms will be enforced using the same methods, and a
visual algorithm on the web pages will guide users. The
web-based system will be piloted for ease of use prior to
data entry go-live.Electronic data protection and confidentiality
The ePCRN safeguards the legal and ethic rights of ser-
vice users through a fully integrated research security
management system consisting of two component parts:
(1) technical specifications built into the DUTY study
database during the development phase, and (2) proced-
ural standards governing the launch and day-to-day use
of the application by DUTY study researchers.
Access to users will be provided through study-specific
logon points in Citrix Access Gateway Advanced Access
Control. Citrix software establishes a secure, encrypted,
connection with the user’s PC, allowing access from
the Internet uniquely to the Citrix Access Gateway
and enabling access to identifiable study data for
authorized users.Data entry in primary care sites
In order to maximise the acceptability and ease of use of
DUTY data collection tools, clinicians working in set-
tings without web access or whose working practice
made web data entry an unwelcome burden, will be able
to opt for paper-based data collection with the support
of the local study centre in entering data, or making al-
ternative arrangements for data entry, on their behalf.
The web-based data collection system will be pre-
sented as the preferred method of data collection, and
practice-based recruiting staff will be strongly encour-
aged and supported to enter CRF data onto the database
directly or, if using paper-based CRFs in the recruitment
interviews, to retrospectively enter the data in a timely
way (consent and registration within 24 hours, and full
eCRF data within 5 working days).
Data entry in the local NHS laboratory and central
research laboratory
Once in the local NHS and SACU research laboratories,
staff will be able to access an anonymised data collection
page, where only study numbers and the data collection
forms for the urine samples can be seen. Laboratory staff
will be asked to log the samples on receipt and enter the
results when available.
Follow-up data entry in research centres
At day 14 from recruitment, and at 3 months, research
staff will enter symptom duration, healthcare resource
utilisation and expenses data from telephone interviews
and practice records respectively onto web-based data
collection forms.
Analysis
The overall aim of the analyses is to derive a validated
clinical prediction rule for UTI among acutely ill chil-
dren presenting to primary care.
Sample size calculation
To estimate the required sample size we drew on our
experience with the EURICA study, which found a UTI
prevalence rate in children aged before their fifth birth-
day of 4% [3]. We considered first the strength of associ-
ation between candidate predictors (symptoms, signs or
dipstick results) and UTI as well as the precision of the
final algorithm’s sensitivity for the detection of UTI. Tak-
ing the most conservative assumptions, i.e. candidate
predictors present in 10% of children and an overall UTI
prevalence of 2%, 3,000 urine sample results are required
to detect an odds ratio of 2.4 with 80% power and a
two-sided alpha of 5%. With an overall prevalence of
UTI of 2%, an algorithm sensitivity of 80% and 3,100
urines, the 95% confidence interval (CI) will be no more
than +/−10%. We propose to recruit 4,000 children with
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gorithm derivation and a further 2,000 children for
validation.
Given the complexity of the statistical analyses, large
number of possible predictors and the need to account
for some missing data in predictor variables, we propose
to recruit at least 7000 children in total (two-thirds for
algorithm derivation; one-third for validation), in order
to maximise the statistical power of the sample).
Statistical analysis
Defining the primary outcome
The first stage of the analysis will investigate the best
combination of microbiology data from the local (NHS)
laboratories and the central research laboratory that can
be used to define urine samples as positive for UTI. We
will agree definitions of UTI positivity for data from
each laboratory (using culture results and white cell
counts) and will cross-tabulate these. Possible disagree-
ments will be examined, and samples classified after dis-
cussion as: (1) “Agree UTI negative”; (2) “Agree UTI
positive”; (3) “Disagree (CL positive, LL negative)”; (4)
“Disagree (CL negative, LL positive)”. If overall between-
laboratory reliability (classified on kappa statistics) is
good, the primary outcome will be defined as positive
for samples classified as (2) “Agree UTI positive”. If
overall agreement is moderate or poor, we will explore
reasons for this. We will stratify according to age of the
child and method of collection (clean catch or nappy
pad), and investigate whether reliability varies between
strata. We will also examine the inference of laboratory
methods (e.g. whether samples are process in boric acid)
and time from sample collection to laboratory
processing.
If the best definition of UTI positivity remains unclear,
then we will select a small number of signs and symp-
toms that the literature suggests are clearly associated
with presence of a UTI. We will examine associations of
UTI positivity with these symptoms, using different defi-
nitions of positivity (e.g. based on central or local labora-
tory, threshold for amount of growth, evidence of
growth of other species, method of sample collection.
We will select the best definition of microbiological
positivity based on the magnitude of associations with
the selected signs and symptoms.
Descriptive analyses
We will use methods appropriate for small proportions
[39] to estimate the prevalence (with 95% confidence
interval) of culture positive urines in acutely unwell chil-
dren aged before their fifth birthday presenting in pri-
mary care. This will be undertaken on the whole dataset.
The degree of variation in prevalence between practices
and geographical areas will be explored using two levelrandom-effects logistic regression models (with practice/
site as a random effect and area as a fixed effect). This
analysis will also explore difference by recruitment site
type (general practice, WICs and CEDs). Children in
whom urine samples are obtained will be compared to
those who are recruited, but no urine sample is obtained
in terms of clinical presentation and demographics.
We will compare the probability of contamination in
samples that are retrieved via a ‘clean catch’ method with
those using nappy pads, controlling for patient and prac-
tice factors in a two level random-effects logistic regres-
sion model (objective 4). We will examine the impact of
timing of sample in relation to the time between obtain-
ing the urine transportation (including day of the week)
and laboratory analysis on the rates of positive and con-
taminated urine samples (e.g. exploring if delayed sam-
ples such as those taken after daily laboratory collection
have an impact on contamination rates).
The sample will then be sub-divided into algorithm
derivation and validation datasets, compromising two-
thirds to one-third of the data set, respectively. This will
be done by randomly selecting practices: all of their
patients will then contribute to one of the two datasets.
Development of clinical prediction rules
We will develop a clinical prediction rule based on the
linear predictor in a logistic regression model in which
the outcome variable is a culture-positive urine result.
Candidate diagnostic variables will be categorised into
demographic background and medical history (for ex-
ample, gender, previous UTI); both specific and general
systemic presenting symptoms and signs (for example
overall illness severity, fever, vomiting); and results from
urine dipstick analysis (nitrite, leukocyte esterase, pro-
tein, blood and glucose). Because of concerns that some
aspects of medical history or demographics may be asso-
ciated with asymptomatic carriage rather than active in-
fection, we will also develop a ‘signs and symptoms’ only
prediction rule. Variables will be included in logistic re-
gression models based on an “inclusive” p value thresh-
old of 0.1. We will check for nonlinear effects of
continuous variables, and will examine candidate inter-
actions specified a priori. Any further candidate interac-
tions will be agreed before analyses commence. Such
effects will be included in the final models as necessary.
We will begin by examining the predictive value
(based on diagnostic odds ratios and C statistics) of the
best predictors from each of the three categories (socio-
demographic and previous medical history, clinical as-
sessment, and dipstick urinalysis) of variables. We will
then examine the additional diagnostic value of present-
ing signs and symptoms (compared with socio-
demographic and medical history alone) and of dipstick
results (compared with the other two categories). We
Downing et al. BMC Infectious Diseases 2012, 12:158 Page 12 of 15
http://www.biomedcentral.com/1471-2334/12/158will examine whether it is possible to identify subgroups
of children in whom dipstick testing is and is not
justified based on their signs and symptoms. The final
algorithm will be characterised based on its sensitivity
and specificity, and positive and negative likelihood
ratios.
Validation of clinical prediction rule
Diagnostic models that are developed using p-value-
based variable selection will inevitably suffer from statis-
tical over-optimism. Therefore, the final models will be
validated using the second dataset, and the published
rule will be based on the linear predictors from the
model re-estimated in this validation dataset. A compari-
son will be made between the results obtained from the
validation and the use of shrinkage based approaches ap-
plied to the original development dataset [40]. A com-
parison will be made between the results obtained from
the validation dataset and the use of shrinkage based
approaches applied to the original development dataset.
The magnitudes of regression coefficients, and overall
diagnostic value of the linear predictor, will be compared
between the primary outcome and other definitions of
culture positivity.
Analyses of follow up data
Children with positive urine cultures (‘contaminants’ and
‘UTIs’) who the clinician felt at recruitment had a sus-
pected UTI will be compared to those who the clinician
felt there was little probability of a UTI in terms of their
subsequent illness course and resource usage over the
next three months.
Risk stratification for clinical practice
In the final stages of analysis, we will examine the sensi-
tivity and specificity of the linear predictor, based on a
set of chosen thresholds for positivity. This will be used
to identify several candidate clinical prediction rules for
comparison in the economic evaluation. We will select
thresholds that provide a range of clinical prediction
rules from high sensitivity/low specificity to low sensitiv-
ity/high specificity.
Minimising Bias
The following design and analytic strategies will be
employed to minimise bias:
(1) Selection bias: where possible we will recruit
consecutive children. We will ask sites to keep a
screening log of patients approached but who did
not take part in the study and reasons for this;
(2) Index test technology: all tests (symptoms, signs,
nappy pads, dipstick tests) will be carried out using
standardised equipment and protocols;(3) Incorporation bias: the reference standard will
consist of culture alone and will not incorporate any
of the index tests;
(4) Review bias: observers assessing the index tests will
differ from and be blind to those assessing the
reference standard (and vice versa);
(5) Verification bias: all children who contribute to the
study will have a urine sample sent to assess the
reference standard. Children in whom it is not
possible to obtain a sample will be excluded from
the analysis. It is unlikely that reasons for failure to
obtain urine samples will be related to the index
tests but we will compare children with and without
urine cultures;
(6) Disease progression bias: we expect the time
between clinical assessment and obtaining the urine
samples to be minimal (no more than 24 hours);
(7) Treatment paradox: for most children, antibiotic
treatment will be started after the urine sample has
been obtained, but we will record where this has
not been possible;
(8) Handling of indeterminate or uninterpretable results
or withdrawals: these parameters will be measured
and considered in the analysis, and;
(9) Appropriateness of the reference standard: use of
>103, but usually >105 CFU/mL of one, but no more
than two uropathogens is likely to detect the
majority of children with UTI, but the second
‘research’ urine result from the SACU laboratory
will allow for sensitivity analyses around different
bacterial concentrations. Where possible, we will
measure all threats to validity (e.g. time between
clinical assessment and obtaining and culturing the
urine sample) that could influence results.
Economic analysis
The aim of the economic analysis is to compare candi-
date clinical prediction rules (CPRs) on: (a) incremental
cost per correct diagnosis of bacteruria, b) incremental
cost per symptomatic day avoided, and c) incremental
lifetime cost per quality adjusted life year, including po-
tential long term complications of UTI from NHS and
societal perspectives.
The cost-effectiveness of each candidate prediction
rule will be compared to a ‘clinical judgement’ testing
strategy and two ‘boundary strategies’: 1) Performing a
urine test in every child meeting the DUTY eligibility
criteria, and 2) No testing, the diagnosis of UTI is made
clinically. The two boundary strategies are not intended
to reflect clinical reality, but provide a reference point
against which other diagnostic strategies can be com-
pared. The cost-effectiveness of each candidate CPR will
be assessed against these three strategies using a deci-
sion analytical model. The face validity of the model
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study team before being finalised.
Cost per correct diagnosis of UTI (diagnostic model)
The diagnostic cost-effectiveness model requires infor-
mation on cost (cost of sample collection, cost of NHS
laboratory testing), probabilities (probability of sample
being obtained and probability of sample being contami-
nated) and diagnostic accuracy parameters (sensitivity
and specificity of the various diagnostic strategies). The
diagnostic accuracy parameters will be derived directly
from the DUTY CRF and the statistical analysis
described above. The probability of sample collection
and contamination will be observed in the DUTY study.
The cost of sample collection and laboratory testing will
be derived from a combination of surveys of NHS la-
boratories and GPs and a time motion study observing
primary care clinical staff as they collect and process
urine samples. The model will estimate the cost per pa-
tient correctly diagnosed. The model will also include
diagnostic strategies that incorporate dipstick testing (e.
g. in those children thought to be a moderate risk of
bacteriuria) with information on a small number of add-
itional parameters (i.e. cost, sensitivity and specificity of
dipstick testing).
Cost per symptomatic day avoided (short term model)
The model will then be extended to estimate cost per
symptomatic day avoided at day 14. A Markov model
will estimate the short-run cost-effectiveness of each
diagnostic strategy. This extension will require informa-
tion on additional parameters including the probabilities
of receiving antibiotics and hospital admission in chil-
dren diagnosed with and without UTI, the cost of anti-
biotics and hospital admission/testing, and the daily
recovery probability for children with bacteriuria treated
with antibiotics, children with bacteriuria not treated
with antibiotics and children without bacteriuria. The
probabilities of antibiotic treatment and hospital admis-
sion will be based on 14 day interviews and review of
patients’ primary care medical notes at 3 months. The
daily recovery probabilities will be based on 14 day inter-
views with parents of children selected for follow-up. As
all children in DUTY will receive a urine test, we will
not be able to observe the recovery of children with bac-
teriuria not treated with antibiotics (i.e. false negatives).
For this transition probability we will use literature esti-
mates of the effect of antibiotic therapy on symptom
duration.
Cost per quality adjusted life year (QALY -long
term model)
The structure of the long-run Markov model will be
based on the a previously developed model [27]. Themodel will provide a link between the number of UTI
attacks that a child will experience, the proportion that
are pyelonephritic, the prevalence of vesicoureteral re-
flux, the probability of progressive renal scarring, the
risk of end stage renal disease (ESRD) and disease man-
agement. Outcome parameters such as probability of
UTI recurrence, renal scarring, ESRD, survival and util-
ity values of renal disease will be based estimates for the
sensitivity and specificity of imaging tests for VUR (e.g.
ultrasound, MCUG), costs of treatment (e.g. antibiotic
prophylaxis, cost of pyelonephritic treatment, dialysis,
transplant), recurrence of UTI, disutilities (pyeloneph-
ritic, dialysis, transplant) and survival [27].
All analyses will be probabilistic, as all parameters will
be entered into the model as distributions. Therefore the
results will be presented as cost-effectiveness acceptabil-
ity curves (CEACs). The CEAC demonstrates which of
several testing strategies is most likely to be cost-
effective at any fixed willingness to pay for a correct
diagnosis. Costs and outcomes occurring after the first
year will be discounted at 3.5%. We will use net monet-
ary benefits and cost-effectiveness acceptability curves,
at plausible willingness to pay thresholds (e.g. £0 to
£50,000 per QALY) to identify the most cost-effective
diagnostic strategies. Deterministic sensitivity analyses
will also be used to evaluate the impact of key para-
meters on results and the influence of various CFU/mL
thresholds on the choice of clinical prediction rule.
Discussion
This paper describes a diagnostic and prospective obser-
vational study in primary care, that aims to recruit at
least 7,000 children aged before their fifth birthday, who
are assessed for any acute, non traumatic, illness
of ≤ 28 days duration. Urine samples will be obtained
from eligible consented children and tested with a dip-
stick before being sent to a local NHS laboratory and a
central research laboratory for microbiological analysis.
This study will provide novel, clinically important in-
formation on the diagnostic features of childhood UTI
to help primary care clinicians improve their diagnostic
efficiency. New insight into the diagnostic value of dip-
stick urinalysis and urine sampling methods will also be
provided.
The observational design of the study will minimise
disruption to normal practice and reduce the research
burden on healthcare professionals, thereby maximising
the applicability and generalisability of findings. In
addition, this study will increase awareness of UTI as a
possible diagnosis in appropriate children under 5 years
old. We will collect full clinical information, including
presenting symptoms and signs, medical history and
clinical diagnosis; urine dipstick data and culture data
from both usual routine local NHS laboratories and
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for derivation and validation of the diagnostic algorithm.
In addition the follow-up data at 14 days and 3 months
will allow for full health economic analysis, providing
cost effectiveness outcomes. Additional useful informa-
tion such as the best way of sampling urine from young
children in primary care, the species and sensitivities of
the infecting organisms, and contamination rates will
also inform care in the future.
The main challenge to the DUTY study is the large
number of participants and urine samples needed. A
substantial number of practices across each of the four
centres will need to be recruited, to provide a large
enough population of potential participants. In addition
to this, parental consent will be required at the same
general practice visit when they are invited to partici-
pate, meaning there is a reliance on parents being willing
and having the time to participate immediately. Despite
the dedicated DUTY recruiting staff on the ground, who
will provide support to practices, study buy-in is needed
from all primary care staff to ensure adequate resources
and infrastructure are in place to facilitate the conduct
of the study. This will require training of all staff
involved at each participating primary care site. A major
contribution from NHS microbiology laboratories will
also be necessary, for processing the increased number
of urine samples received from primary care sites.
This study will rely on sampling methods most com-
monly used currently in UK primary care, namely nappy
pad and clean catch. Suprapubic aspiration and catheter-
isation methods are neither feasible nor appropriate for
primary care. Nappy pad sampling may carry an
increased risk of contamination or un-interpretable
results. This may lead to the exclusion of some results
from the main analysis. However, this will be minimised
by obtaining clean catch samples where possible. Lastly,
the electronic data capture on the database has been
designed to allow for all parties to enter data separately.
A challenge will be to ensure all data is entered into the
database in a timely way, to allow for both the real time
monitoring of recruitment and urine sample location, as
well as the conduction of the follow-up interviews
within the tight timeframe.
In summary, this will be one of the largest studies of
its kind undertaken in primary care, involving obtaining
clinical samples from children, and will help guide man-
agement of the acutely unwell child, which is a common
and important aspect of primary health care delivery.
Improved assessment and diagnosis may lead to more
appropriate microbiological and point of care testing
and more timely treatment and investigation of those
children who are most likely to benefit, while reducing
unnecessary treatment and investigation among those
that are most unlikely to benefit. This is likely toimprove outcomes for individual patients and may help
prevent long-term sequelae. The overall outcome of the
study will be to achieve a more consistent approach in
the clinical care of a common condition, based on accur-
ate diagnosis and effective clinical management.
Endnotes
a This paper will use the term ‘parent’ to refer to the per-
son with legal responsibility for the child, therefore as ap-
plied in this paper the term also encompasses carers
(foster parents, legal guardians etc.).
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